Evaluation of Clinical Outcomes of Unruptured bAVMs Treated With Medical Management Alone Based on Multimodal CT
Launched by BEIJING TIANTAN HOSPITAL · Jul 4, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the outcomes of patients with unruptured brain arteriovenous malformations (bAVMs) who are being treated with medical management only, using advanced imaging techniques called multimodal CT scans. The goal is to understand how the characteristics of these bAVMs, such as their structure and blood flow patterns, can help predict various health outcomes, like the risk of bleeding, new seizures, or other neurological problems. Researchers will closely monitor patients over three years to gather important information about these conditions.
To participate in this study, individuals must have a confirmed diagnosis of bAVMs and no history of bleeding related to them. They should not have had any previous treatments or any other specific types of vascular issues. Participants will undergo regular follow-ups at six months, one year, two years, and three years to track their health and any changes in their condition. This study is actively recruiting participants of all genders, and it aims to improve our understanding of how to manage and treat brain arteriovenous malformations effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with confirmed diagnosis of brain arteriovenous malformations in the brain, basal ganglia, thalamus, corpus callosum, cerebellum and other locations.
- • 2. Patients with no history of previous arteriovenous malformation-related hemorrhage and no arteriovenous malformation-related hemorrhage confirmed by CT examination.
- • 3. Patients with Radiographic examinations completed without any treatment
- Exclusion Criteria:
- • 1. Patients with simple arteriovenous fistula.
- • 2. Patients with combined dural arteriovenous fistulas.
- • 3. Arteriovenous malformations occurring in the spinal cord.
- • 4. Pregnant patients were not included in this study.
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Nanjing, Jiangsu, China
Beijing, Beijing, China
Zhengzhou, Hennan, China
Beijing, Beijing, China
Patients applied
Trial Officials
Dong Zhang, Doctor
Study Chair
Beijing Tiantan Hospital, Beijing Hospital
Shaosen Zhang, Doctor
Study Director
Beijing Tiantan Hospital
Guosheng Zhou
Principal Investigator
The First Affiliated Hospital of Zhengzhou University
Yongbo Yang
Principal Investigator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials